Ophthalmic Business News

NEW YORK — In this Healio Video Perspective from OSN New York, Susan Benton, president of Thea Pharma, discusses Iyuzeh for primary open-angle glaucoma. The treatment launched during the meeting.

Physicians of all specialties are likely aware of health savings accounts and their use by patients and doctors alike to pay for health-related expenses.

In the phase 3 BALATON and COMINO studies, Vabysmo demonstrated vision maintenance and anatomic improvements up to week 72 in macular edema secondary to retinal vein occlusion, or RVO, according to a Genentech press release.

In this episode, hosts Laura Enyedi, MD, and Susan MacDonald, MD, sit down and chat with guests Carey Powers, Ali Salo and Tiffany Haynes, to discuss women in leadership, live from the Women in Ophthalmology meeting.

Zeiss Medical Technology has partnered with Boehringer Ingelheim to create predictive analytics to aid with early detection of eye diseases.

As an orthopedic surgeon and an attorney/wealth manager who has worked with more than 1,000 physicians, we know that asset protection and tax planning are two of the highest interest planning areas for physicians.

Patients with wet age-related macular degeneration who were switched from aflibercept alone to a combination of aflibercept and UBX1325 at week 24 maintained vision gains through 48 weeks in part B of the phase 2 ENVISION study.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more.

The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists or parasympatholytic agents, according to a press release from Ocuphire Pharma and Viatris.

Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.